RxDoctor Payments Data

Lillian Graf, MD

Dermatology · Bayside, NYNPI 1881764454

Payments from drug & device makers

$7,585in general payments, 2019–2025

Across 374 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$876
  • Incyte Corporation$850
  • AbbVie$764
  • Johnson & Johnson$698
  • Pfizer$428
  • Galderma Laboratories, L.p.$415
  • plus $4K from 28 others

What the payments were for

  • Food & beverage$7,47699%
  • Education$1091%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,585 in reported general payments places this provider in the 65th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$484,383
Medicare patients
1,259
Services billed
9,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast12$57,891
Tavaborole35$8,368
JubliaEfinaconazole11$7,868
Ivermectin22$6,130
Clobetasol Propionate133$5,543
Ketoconazole248$4,014
Tretinoin39$2,997
Fluorouracil49$2,705
Tacrolimus18$2,664
Metronidazole35$1,698
Clindamycin Phosphate54$1,687
Ciclopirox33$1,378
Mupirocin205$1,357
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc38$1,329
Ammonium Lactate45$1,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$322$57,89112 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$222$7,86811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,151 dermatology providers in New York.

Other dermatology in Bayside

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →